glp-1 ra drugs Drug Comparison in Diabetes and Obesity Treatment GLP-1 Receptor Agonist Market Size
Description
Despite a significant improvement in the treatment of T2D and CVD over the past few decades, reducing CVD in patients with T2D solely with an optimal glycemic control has been challenging [2]
J Clin Invest 2014;124:4223-6.ArticlePubMedPMC 100
Several preclinical studies have shown that lanifibranor has both antifibrotic and positive metabolic effects
doi: 10.1016/j.pharmthera.2015.08.004
